![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PharmaTher is evolving to become a leader in ketamine-based solutions for mental health, neurological and pain disorders, and partnering with Alcami as our exclusive manufacturer for the clinical and commercial supply of ketamine.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: PharmaTher
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 19, 2021
Details:
Alcami is providing commercial manufacturing services for Trevena's newly approved OLINVYK. OLINVYK (oliceridine) injection is an opioid approved in adults for the management of acute pain severe enough to require an intravenous opioid analgesic.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Trevena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 26, 2020